Using What We Already Have: Uncovering New Drug Repurposing Strategies in Existing Omics Data.


Journal

Annual review of pharmacology and toxicology
ISSN: 1545-4304
Titre abrégé: Annu Rev Pharmacol Toxicol
Pays: United States
ID NLM: 7607088

Informations de publication

Date de publication:
06 01 2020
Historique:
pubmed: 25 7 2019
medline: 12 11 2020
entrez: 25 7 2019
Statut: ppublish

Résumé

The promise of drug repurposing is to accelerate the translation of knowledge to treatment of human disease, bypassing common challenges associated with drug development to be more time- and cost-efficient. Repurposing has an increased chance of success due to the previous validation of drug safety and allows for the incorporation of omics. Hypothesis-generating omics processes inform drug repurposing decision-making methods on drug efficacy and toxicity. This review summarizes drug repurposing strategies and methodologies in the context of the following omics fields: genomics, epigenomics, transcriptomics, proteomics, metabolomics, microbiomics, phenomics, pregomics, and personomics. While each omics field has specific strengths and limitations, incorporating omics into the drug repurposing landscape is integral to its success.

Identifiants

pubmed: 31337270
doi: 10.1146/annurev-pharmtox-010919-023537
doi:

Substances chimiques

Pharmaceutical Preparations 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

333-352

Subventions

Organisme : NCATS NIH HHS
ID : UL1 TR002243
Pays : United States

Auteurs

Jill M Pulley (JM)

Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee 37203, USA.

Jillian P Rhoads (JP)

Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee 37203, USA.

Rebecca N Jerome (RN)

Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee 37203, USA.

Anup P Challa (AP)

Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee 37203, USA.

Kevin B Erreger (KB)

Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee 37203, USA.

Meghan M Joly (MM)

Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee 37203, USA.

Robert R Lavieri (RR)

Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee 37203, USA.

Kelly E Perry (KE)

Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee 37203, USA.

Nicole M Zaleski (NM)

Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee 37203, USA.

Jana K Shirey-Rice (JK)

Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee 37203, USA.

David M Aronoff (DM)

Department of Medicine, Division of Infectious Diseases, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA.
Departments of Obstetrics and Gynecology, and Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA; email: d.aronoff@vumc.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH